Literature DB >> 20656212

Immunosenescence and cancer.

Graham Pawelec1, Evelyna Derhovanessian, Anis Larbi.   

Abstract

Age is a major risk factor for many cancers. Although this is usually viewed in the context of the cell biology, we argue here that age-associated changes to immunity may also contribute to the age-associated increasing incidence of most cancers. This is because cancers are immunogenic (at least initially), and the immune system can and does protect against tumourigenesis. However, immune competence tends to decrease with age, a phenomenon loosely termed "immunosenescence", implying that decreased immunosurveillance against cancer could also contribute to increased disease in the elderly. This review weighs some of the evidence for and against this possibility. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20656212     DOI: 10.1016/j.critrevonc.2010.06.012

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  34 in total

1.  Mast cell-directed recruitment of MHC class II positive cells and eosinophils towards mesenteric lymphatic vessels in adulthood and elderly.

Authors:  Victor Chatterjee; Anatoliy A Gashev
Journal:  Lymphat Res Biol       Date:  2014-03       Impact factor: 2.589

2.  The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer.

Authors:  Ming-Ching Lee; Daniel H Buitrago; Kyuichi Kadota; Hideki Ujiie; Kaitlin Woo; Camelia S Sima; William D Travis; David R Jones; Prasad S Adusumilli
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

Review 3.  Thymus: the next (re)generation.

Authors:  Mohammed S Chaudhry; Enrico Velardi; Jarrod A Dudakov; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2016-05       Impact factor: 12.988

Review 4.  Peto's Paradox: evolution's prescription for cancer prevention.

Authors:  Aleah F Caulin; Carlo C Maley
Journal:  Trends Ecol Evol       Date:  2011-04       Impact factor: 17.712

5.  Age-related oxidative stress compromises endosomal proteostasis.

Authors:  Elvira S Cannizzo; Cristina C Clement; Kateryna Morozova; Rut Valdor; Susmita Kaushik; Larissa N Almeida; Carlo Follo; Ranjit Sahu; Ana Maria Cuervo; Fernando Macian; Laura Santambrogio
Journal:  Cell Rep       Date:  2012-07-12       Impact factor: 9.423

Review 6.  The circadian clock in cancer development and therapy.

Authors:  Loning Fu; Nicole M Kettner
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

7.  Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysis.

Authors:  Willemien van de Water; Caroline Seynaeve; Esther Bastiaannet; Christos Markopoulos; Steve E Jones; Daniel Rea; Annette Hasenburg; Hein Putter; Elysée T M Hille; Robert Paridaens; Anton J M de Craen; Rudi G J Westendorp; Cornelis J H van de Velde; Gerrit-Jan Liefers
Journal:  Oncologist       Date:  2012-12-20

Review 8.  Immune Checkpoint Inhibitors in Older Adults.

Authors:  Rawad Elias; Joshua Morales; Yasser Rehman; Humera Khurshid
Journal:  Curr Oncol Rep       Date:  2016-08       Impact factor: 5.075

9.  Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials.

Authors:  Qingyuan Huang; Hua Zhang; Josephine Hai; Mark A Socinski; Eric Lim; Haiquan Chen; Justin Stebbing
Journal:  Oncoimmunology       Date:  2018-06-20       Impact factor: 8.110

10.  Age-Associated Changes in Adverse Events Arising From Anti-PD-(L)1 Therapy.

Authors:  Xinyi Huang; Tiantian Tian; Yan Zhang; Shengjian Zhou; Pingping Hu; Jiandong Zhang
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.